Journal Article

DKFZ-2026-00618

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Outcomes of stereotactic body radiotherapy for bone oligometastases in older patients - A European multicenter cohort study.

Nägler, F. ; Schäfer, S. ; Seiler, I. ; von Wachter, C. ; Balermpas, P. ; Loi, M. ; Bonomo, P. ; Slavik, M. ; Burkon, P. ; Kästner, L. ; Meents, J. ; Lohaus, F.DKFZ* ; Willner, J. ; Schunn, A. S. ; Drabke, S. ; Klischies, K. ; Wittenstein, O. ; Bank, P. ; Partl, R. ; Müller, J. A. ; Gawish, A. ; Grün, A. ; Baehr, A. ; Trommer, M. ; Gkika, E. ; Mader, T. ; Holy, R. ; Frerker, B. ; Ehret, F.DKFZ* ; Rühle, A. ; Guckenberger, M. ; Moustakis, C. ; Brunner, T. B. ; Blanck, O. ; Boda-Heggemann, J. ; Nicolay, N. H.

2026
Elsevier Science Amsterdam [u.a.]

Abstract: Outcome patterns for stereotactic body radiotherapy (SBRT) of bone oligometastases (BoM) especially for older patients are inadequately defined. We aimed to evaluate oncological outcomes and tolerability of SBRT for BoM in older patients.Patients ≥70 years treated with SBRT for BoM between 2010 and 2024 at 20 European centers were analyzed and compared to patients <70 years. Outcomes included local recurrence (LR)/ freedom from LR (FFLR), progression-free survival (PFS), overall survival (OS), and adverse events.789 patients with 1079 BoM were analyzed. Median age was 68 years (range: 19-91), and 355 patients (45.0%) were ≥70 years. Most common primary tumors were prostate (57.4%), breast (13.8%), and lung cancers (10.5%). LR at 3 years was 9.3% (CI: 6.0-12.8%) in patients <70 years and 11.7% (CI: 7.1-16.8%) in patients ≥70 years (p = 0.39). Grade-3 adverse events occurred in 1.8% of patients <70 years and 1.4% ≥70 years. No grade-4/5 adverse events were observed. Fracture rates were 2.9% for patients <70 years, and 1.8% ≥70 years. A higher metastatic volume was associated with reduced FFLR (Hazard ratio [HR] 1.006; p = 0.02), PFS (HR 1.003; p = 0.05), and OS (HR 1.003; p = 0.04). A better performance status was related to improved PFS (HR 0.98; p < 0.01) and OS (HR 0.96; p < 0.001), while age was not a significant factor.This multicenter cohort analysis showed that SBRT of BoM is effective and well tolerated even in older patients. There were no significant differences in outcomes or side effects including fracture rates across patient age groups.

Keyword(s): Bone metastases ; Non-spine metastases ; Older patients ; SBRT ; Spine metastases ; Stereotactic radiotherapy ; metastasis-directed therapy (MDT)

Note: epub

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Dresden (DD01)
2. DKTK Koordinierungsstelle Berlin (BE01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2026

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---